Hormonal treatment of endometrial cancer: Past, present and future

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 3, 2001, Pages 469-489

  Podczaski, Edward ^a   Mortel, Rodrigue ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Endometrial cancer; Oestrogen receptor; Progesterone receptor; Progestins; Tamoxifen

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; GESTAGEN; GONADORELIN DERIVATIVE; HYDROXYPROGESTERONE CAPROATE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELPHALAN; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HORMONE RESPONSE; HUMAN; HYSTERECTOMY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

EID: 0034929501     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2000.0189     Document Type: Article

References (90)

1. Histologic effects of progestins on hyperplasia and carcinoma in situ of the endometrium
2. Effects of 17-alpha-hydroxy progesterone caproate on metastatic endometrial cancer
3. The role of progesterone in human endometrial cancer
4. A progestogen for treatment of advanced endometrial cancer
5. Sequence and expression of human estrogen receptor complementary DNA
6. The steroid and thyroid hormone receptor superfamily
7. Evolution of the nuclear receptor gene superfamily
8. Nuclear receptors enhance our understanding of transcription regulation
9. The molecular pharmacology of ovarian steroid receptors
10. Mechanism of nuclear localization of the progesterone receptor: Evidence for interaction between monomers
11. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor
12. Structure and function of the oestrogen receptor
13. Solution structure of the DNA-binding domain of the oestrogen receptor
14. A canonical structure for the ligand-binding domain of nuclear receptors
15. A complex containing N-CoR, mSin3, and histone deacetylase mediates transcriptional repression
16. Sinful repression
17. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-I enhancer
18. Tamoxifen activation of the estrogen receptor/AP-I pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
19. ERβ: Identification and characterization of a novel human estrogen receptor
20. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern
21. Estrogen receptors α and β form heterodimers on DNA
22. The complete primary structure of human estrogen receptor β (hERβ) and its heterodimerization with ER α in vivo and in vitro
23. Endometrial adenocarcinoma in women under 25 years of age
24. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women
25. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
26. Pregnancy after in vitro fertilization in a patient with stage I endometrial carcinoma treated with progestins
27. Endometrial carcinoma Stage I - Grade II. Conservative treatment followed by a healthy twin pregnancy
28. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer
29. A randomized trial of progestogens in the primary treatment of endometrial carcinoma
30. A controlled clinical study of adjuvant medroxyprogesterone acetate (MPA) therapy in pathologic stage I endometrial carcinoma with myometrial invasion
31. A randomized trial of adjuvant progestagen in early endometrial cancer
32. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial
33. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma
34. Effects of progestational agents in treatment of endometrial carcinoma
35. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: Results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience
36. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma
37. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations
38. A randomized trial of medroxyprogesterone acetate (MPA) 200 mg versus 1000 mg daily in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study
39. High-dose megesterol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
40. Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administration
41. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to antiestrogen
42. Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma
43. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium
44. Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin. Clinical correlates
45. Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapy
46. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma
47. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen and progesterone receptor expression
48. 2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?
49. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications
50. Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma
51. Tamoxifen in the treatment of breast cancer
52. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
53. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
54. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
55. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
56. Differential ligand activation of estrogen receptors ERα and ERβ at AP-I sites
57. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
58. Molecular basis of agonism and antagonism in the oestrogen receptor
59. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
60. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxy-tamoxifen
61. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
62. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions
63. Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment
64. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study
65. Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia
66. Phase II study of megestrol (M) and megestrol + tamoxifen (T) in advanced endometrial carcinoma: An Eastern Cooperative Oncology Group (ECOG) study
67. Treatment of recurrent or metastatic poorly differentiated adenocarcinomas of the endometrium with tamoxifen and medroxyprogesterone acetate
68. Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate
69. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines
70. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis
71. A new treatment for endometrial cancer with gonadotropin releasing-hormone analogue
72. Long-term follow-up of gonadotropin-releasing hormone analog treatment for recurrent endometrial cancer
73. A phase II study of leuprolide in advanced/recurrent endometrial cancer
74. Leuprolide in the treatment of endometrial cancer
75. Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate
76. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens
77. Multidrug treatment of advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study
78. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-platinum, and megestrol acetate
79. Melphalan, 5-Fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma
80. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status
81. Treatment of recurrent and metastatic endometrial cancer with cisplatin doxorubicin, cyclophosphamide, and megestrol acetate
82. Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxy-progesterone acetate
83. Cisplatin, adriamycin, etoposide, megesterol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma
84. Chemotherapy plus sequential hormone therapy for advanced and recurrent endometrial carcinoma: A phase II study
85. Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology
86. Differences in estrogen receptor α variant messenger RNAs between normal human breast tissue and primary breast carcinomas
87. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma
88. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model
89. Mutations of the estrogen receptor in endometrial carcinoma: Evidence of an association with high tumor grade
90. Mutational analysis of the estrogen-receptor gene in endometrial carcinoma